Melanoma
📧 Sign up to get email alerts when something new happens for Melanoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2021-06-16Clinical Trial Update: Evaluation of Cytokine Biomarkers in Melanoma Patients During Immunotherapy [Phase 2]
Phase 2 trial evaluating cytokine biomarkers in melanoma patients undergoing immunotherapy.
-
CLINICAL_TRIALS trial_result · 2021-06-15Clinical Trial Update: Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV Melanoma [Phase 3]
A Phase 3 trial comparing nivolumab to ipilimumab as adjuvant therapy to prevent recurrence after complete resection of stage IIIb/c or stag…
-
CLINICAL_TRIALS trial_result · 2021-06-15Clinical Trial Update: Nivolumab Combined With Ipilimumab Followed by Nivolumab Monotherapy as First-Line Treatment for Patients With Advanced Melanoma [Phase 3]
Phase 3 trial evaluating nivolumab with ipilimumab followed by nivolumab monotherapy as first-line treatment for advanced melanoma has compl…
-
CLINICAL_TRIALS trial_result · 2021-06-08Clinical Trial Update: Aldesleukin in Participants With Metastatic Renal Cell Carcinoma or Metastatic Melanoma [Phase 4]
Phase 4 clinical trial update for Aldesleukin in participants with metastatic renal cell carcinoma or metastatic melanoma has completed with…
-
CLINICAL_TRIALS trial_result · 2021-06-08Clinical Trial Update: A Study of E7050 in Combination With E7080 in Participants With Advanced Solid Tumors (Dose Escalation) and in Participants With Recurrent Glioblastoma or Unresectable Stage III or Stage IV Melanoma After Prior Systemic Therapy (Expansion Cohort and Phase 2) [Phase 1, Phase 2]
A phase 1/2 study of E7050 in combination with E7080 in advanced solid tumors and specific recurrent/unresectable cancers; the trial status …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2021-05-28Clinical Trial Update: A Rollover Study for Patients Who Received Tremelimumab in Other Protocols, to Allow the Patients Access to Tremelimumab Until This Agent Becomes Commercially Available or Development is Discontinued. [Phase 2]
A Phase 2 rollover study of tremelimumab for patients who had received it in other protocols, to provide continued access until it becomes c…
-
CLINICAL_TRIALS trial_result · 2021-05-27Clinical Trial Update: Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery [Phase 3]
This is a Phase 3 clinical trial update comparing ipilimumab to high-dose interferon alfa-2b in patients with resected high-risk Stage III–I…
-
FDA approval · 2021-05-19FDA Approved: KIT FOR THE PREPARATION OF LYMPHOSEEK (TECHNETIUM TC 99M TILMANOCEPT) — Supplemental Application (Cardinal Health 414, LLC)
FDA approved a supplemental application for the Kit for the Preparation of Lymphoseek (Technetium-99m Tilmanocept) to prepare Lymphoseek for…
-
FDA approval · 2021-05-07FDA Approved: MEKINIST — Supplemental Application (Novartis Pharmaceuticals Corporation)
FDA approved a supplemental application for Mekinist (trametinib) from Novartis Pharmaceuticals Corporation.
-
CLINICAL_TRIALS trial_result · 2021-04-29Clinical Trial Update: Safety Study of a Helper Peptide Vaccine Plus Adjuvant Combinations for the Treatment of Melanoma [Phase 1, Phase 2]
A safety study of a helper peptide vaccine plus adjuvant combinations for melanoma was conducted in Phase 1/2 and terminated with results po…
-
CLINICAL_TRIALS trial_result · 2021-04-28Clinical Trial Update: Dabrafenib/Trametinib/Hydroxychloroquine for Advanced Pretreated BRAF V600 Mutant Melanoma [Phase 1, Phase 2]
Clinical trial update evaluating dabrafenib, trametinib, and hydroxychloroquine in advanced pretreatment BRAF V600 mutant melanoma (Phase 1/…
-
CLINICAL_TRIALS trial_result · 2021-04-20Clinical Trial Update: Vaccine Therapy With or Without Cyclophosphamide in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma [Phase 1, Phase 2]
A phase 1/2 clinical trial evaluating a vaccine therapy with or without cyclophosphamide in patients who had surgery for stage II–IV melanom…
-
CLINICAL_TRIALS trial_result · 2021-04-15Clinical Trial Update: Uptake and Biodistribution of 89Zirconium-labeled Ipilimumab in Ipilimumab Treated Patients With Metastatic Melanoma [Phase 2]
Phase 2 clinical trial update evaluating uptake and biodistribution of 89Zirconium-labeled ipilimumab in patients with metastatic melanoma w…
-
CLINICAL_TRIALS trial_result · 2021-04-08Clinical Trial Update: Study of NY-ESO-1 ISCOMATRIX® in Patients With High-risk, Resected Melanoma [Phase 2]
Phase 2 trial evaluating NY-ESO-1 ISCOMATRIX in high-risk, resected melanoma has completed with posted results.
-
CLINICAL_TRIALS trial_result · 2021-04-05Clinical Trial Update: Regorafenib, C-kit Mutated Malignant Melanoma, 2nd Line Therapy [Phase 2]
Phase 2 clinical trial update evaluating regorafenib for second-line treatment of C-kit mutated malignant melanoma.
-
CLINICAL_TRIALS trial_result · 2021-04-01Clinical Trial Update: Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Investigational Treatments in Combination With Standard of Care Immune Checkpoint Inhibitors in Participants With Advanced Melanoma [Phase 1]
Phase 1 study evaluating safety, tolerability, and pharmacodynamics of investigational treatments in combination with standard of care immun…
-
CLINICAL_TRIALS trial_result · 2021-03-24Clinical Trial Update: MK-3475 in Melanoma and NSCLC Patients With Brain Metastases [Phase 2]
Phase 2 trial update for MK-3475 (pembrolizumab) in melanoma and non-small cell lung cancer patients with brain metastases has completed wit…
-
CLINICAL_TRIALS trial_result · 2021-03-24Clinical Trial Update: T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer [Phase 2]
Phase 2 trial update on T cell receptor immunotherapy targeting NY-ESO-1 in NY-ESO-1 expressing cancers; study is completed with results pos…
-
CLINICAL_TRIALS trial_result · 2021-03-17Clinical Trial Update: Study to Investigate the Objective Response Rate of Dabrafenib in Combination With Trametinib in Subjects With BRAF V600 Mutation-Positive Melanoma [Phase 2]
Phase 2 trial update evaluating dabrafenib plus trametinib for BRAF V600 mutation-positive melanoma has completed with posted results.
-
CLINICAL_TRIALS trial_result · 2021-03-11Clinical Trial Update: Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer [Phase 2]
Phase II trial of the CDK inhibitor PD 0332991 (palbociclib) in various adult solid tumors including colon and breast cancers has completed …
-
CLINICAL_TRIALS trial_result · 2021-03-11Clinical Trial Update: Safety of TKI258 in Advanced/Metastatic Melanoma Subjects [Phase 1, Phase 2]
Clinical trial update reporting safety data for TKI258 in advanced/metastatic melanoma across Phase 1 and Phase 2.
-
CLINICAL_TRIALS trial_result · 2021-03-05Clinical Trial Update: Nivolumab Plus Relatlimab or Ipilimumab in Metastatic Melanoma Stratified by MHC-II Expression [Phase 2]
Phase 2 trial update evaluating nivolumab plus relatlimab or nivolumab plus ipilimumab in metastatic melanoma stratified by MHC-II expressio…
-
CLINICAL_TRIALS trial_result · 2021-02-21Clinical Trial Update: Ipilimumab vs Ipilimumab Plus Nivolumab in Patients With Stage III-IV Melanoma Who Have Progressed or Relapsed on PD-1 Inhibitor Therapy [Phase 2]
Phase 2 trial comparing ipilimumab alone versus ipilimumab plus nivolumab in melanoma patients who progressed on PD-1 inhibitors; results co…
-
CLINICAL_TRIALS trial_result · 2021-02-18Clinical Trial Update: Ipilimumab With Carboplatin and Paclitaxel in Patients With Unresectable Stage III and Stage IV Melanoma [Phase 2]
Phase 2 trial evaluating ipilimumab with carboplatin and paclitaxel in patients with untreated unresectable stage III or stage IV melanoma.
-
CLINICAL_TRIALS trial_result · 2021-02-01Clinical Trial Update: HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma [Phase 4]
Phase 4 trial update of HD IL-2 plus vemurafenib in patients with BRAF mutation-positive metastatic melanoma; study terminated.